Comment prévenir les infections à virus oncogènes ?
La prévention inclut la vaccination, l'éducation et des pratiques sexuelles sûres.
PréventionVaccinationÉducation à la santé
#2
La vaccination est-elle efficace contre tous les virus oncogènes ?
Non, la vaccination est spécifique à certains virus, comme le HPV et l'hépatite B.
VaccinationVirus du papillome humainHépatite B
#3
Quels comportements à risque doivent être évités ?
Éviter les rapports sexuels non protégés et le partage de matériel d'injection.
Comportements à risquePréventionInfections virales
#4
Les dépistages réguliers sont-ils recommandés ?
Oui, des dépistages réguliers peuvent aider à détecter précocement les cancers associés.
DépistagePréventionCancer
#5
L'éducation à la santé joue-t-elle un rôle dans la prévention ?
Oui, l'éducation à la santé est cruciale pour sensibiliser aux risques et aux préventions.
Éducation à la santéPréventionInfections virales
Traitements
5
#1
Quels traitements sont disponibles pour ces infections ?
Les traitements incluent la chimiothérapie, la radiothérapie et les antiviraux.
ChimiothérapieRadiothérapieAntiviraux
#2
Les traitements sont-ils différents selon le virus ?
Oui, le traitement varie selon le type de virus et le cancer associé.
Infections viralesOncologieTraitement
#3
La vaccination peut-elle prévenir ces infections ?
Oui, certaines vaccinations, comme celles contre le HPV, peuvent prévenir des infections oncogènes.
VaccinationVirus du papillome humainPrévention
#4
Les traitements sont-ils efficaces à tous les stades ?
L'efficacité des traitements dépend du stade de la maladie au moment du diagnostic.
Stade de la maladieTraitementInfections virales
#5
Y a-t-il des effets secondaires aux traitements ?
Oui, les traitements peuvent entraîner des effets secondaires variés, comme la fatigue.
Effets secondairesChimiothérapieRadiothérapie
Complications
5
#1
Quelles complications peuvent survenir avec ces infections ?
Les complications incluent le développement de cancers et des maladies chroniques.
ComplicationsCancerMaladies chroniques
#2
Les infections à virus oncogènes augmentent-elles le risque de cancer ?
Oui, elles sont souvent liées à un risque accru de divers types de cancer.
Risque de cancerInfections viralesOncologie
#3
Peut-on avoir plusieurs infections à virus oncogènes ?
Oui, il est possible d'être infecté par plusieurs virus oncogènes simultanément.
Infections viralesCo-infectionsOncologie
#4
Les complications sont-elles réversibles ?
Certaines complications peuvent être traitées, mais d'autres peuvent être irréversibles.
ComplicationsTraitementInfections virales
#5
Comment les complications affectent-elles la qualité de vie ?
Les complications peuvent gravement affecter la qualité de vie et nécessiter des soins continus.
Qualité de vieComplicationsSoins de santé
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque ?
Les principaux facteurs incluent l'exposition à des virus, le tabagisme et l'immunodépression.
Facteurs de risqueImmunodépressionTabagisme
#2
L'âge influence-t-il le risque d'infection ?
Oui, le risque d'infection et de cancer augmente avec l'âge.
ÂgeFacteurs de risqueInfections virales
#3
Les antécédents familiaux jouent-ils un rôle ?
Oui, des antécédents familiaux de cancer peuvent augmenter le risque d'infections oncogènes.
Antécédents familiauxFacteurs de risqueCancer
#4
Le mode de vie affecte-t-il le risque d'infection ?
Oui, un mode de vie sain peut réduire le risque d'infections et de cancers associés.
Mode de viePréventionInfections virales
#5
Les infections chroniques augmentent-elles le risque ?
Oui, les infections chroniques peuvent augmenter le risque de développer des cancers.
Infections chroniquesRisque de cancerOncologie
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Infections à virus oncogènes : Questions médicales les plus fréquentes",
"headline": "Infections à virus oncogènes : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Infections à virus oncogènes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-25",
"dateModified": "2026-02-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Infections à virus oncogènes"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Maladies virales",
"url": "https://questionsmedicales.fr/mesh/D014777",
"about": {
"@type": "MedicalCondition",
"name": "Maladies virales",
"code": {
"@type": "MedicalCode",
"code": "D014777",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C01.925"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Infections à virus Epstein-Barr",
"alternateName": "Epstein-Barr Virus Infections",
"url": "https://questionsmedicales.fr/mesh/D020031",
"about": {
"@type": "MedicalCondition",
"name": "Infections à virus Epstein-Barr",
"code": {
"@type": "MedicalCode",
"code": "D020031",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C01.925.928.313"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Infections à virus oncogènes",
"alternateName": "Tumor Virus Infections",
"code": {
"@type": "MedicalCode",
"code": "D014412",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Alejandro Olmedo-Velarde",
"url": "https://questionsmedicales.fr/author/Alejandro%20Olmedo-Velarde",
"affiliation": {
"@type": "Organization",
"name": "Department of Plant and Environmental Protection Sciences, University of Hawaii, Honolulu, HI, United States."
}
},
{
"@type": "Person",
"name": "John Hu",
"url": "https://questionsmedicales.fr/author/John%20Hu",
"affiliation": {
"@type": "Organization",
"name": "Department of Plant and Environmental Protection Sciences, University of Hawaii, Honolulu, HI, United States."
}
},
{
"@type": "Person",
"name": "Jun Dai",
"url": "https://questionsmedicales.fr/author/Jun%20Dai",
"affiliation": {
"@type": "Organization",
"name": "Experimental Animal Center, Zunyi Medical University, Zunyi, 563099, China; Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, China. Electronic address: 1341481255@qq.com."
}
},
{
"@type": "Person",
"name": "Yiyi Feng",
"url": "https://questionsmedicales.fr/author/Yiyi%20Feng",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Veterinary Microbiology and Animal Infectious Diseases, College of Animal Sciences and Veterinary Medicine, Guangxi University, Nanning, 530004, Guangxi, China. Electronic address: 654956883@qq.com."
}
},
{
"@type": "Person",
"name": "Ying Liao",
"url": "https://questionsmedicales.fr/author/Ying%20Liao",
"affiliation": {
"@type": "Organization",
"name": "Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, China. Electronic address: liaoying@shvri.ac.cn."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Interventions for BK virus infection in kidney transplant recipients.",
"datePublished": "2024-10-09",
"url": "https://questionsmedicales.fr/article/39382091",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD013344.pub2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cultured Renal Proximal Tubular Epithelial Cells Resemble a Stressed/Damaged Kidney While Supporting BK Virus Infection.",
"datePublished": "2023-05-11",
"url": "https://questionsmedicales.fr/article/37166336",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1128/jvi.00343-23"
}
},
{
"@type": "ScholarlyArticle",
"name": "Deep Sequencing and Molecular Characterisation of BK Virus and JC Virus WHO International Reference Materials for Clinical Diagnostic Use.",
"datePublished": "2023-05-30",
"url": "https://questionsmedicales.fr/article/37376589",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/v15061289"
}
},
{
"@type": "ScholarlyArticle",
"name": "A new evaluation of the rearranged non-coding control region of JC virus in patients with colorectal cancer.",
"datePublished": "2024-08-12",
"url": "https://questionsmedicales.fr/article/39134946",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12885-024-12684-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Histone deacetylase III interactions with BK polyomavirus large tumor antigen may affect protein stability.",
"datePublished": "2023-07-18",
"url": "https://questionsmedicales.fr/article/37464367",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12985-023-02128-6"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Infection",
"item": "https://questionsmedicales.fr/mesh/D007239"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies virales",
"item": "https://questionsmedicales.fr/mesh/D014777"
},
{
"@type": "ListItem",
"position": 4,
"name": "Infections à virus oncogènes",
"item": "https://questionsmedicales.fr/mesh/D014412"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Infections à virus oncogènes - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Infections à virus oncogènes",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Infections à virus oncogènes",
"description": "Comment diagnostiquer une infection à virus oncogène ?\nQuels tests sont utilisés pour détecter les virus oncogènes ?\nLes marqueurs tumoraux sont-ils utiles dans le diagnostic ?\nPeut-on diagnostiquer ces infections par des symptômes ?\nQuel rôle joue l'historique médical dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D014412#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Infections à virus oncogènes",
"description": "Quels sont les symptômes courants des infections à virus oncogènes ?\nLes infections à virus oncogènes causent-elles des symptômes spécifiques ?\nComment les symptômes évoluent-ils avec le temps ?\nLes symptômes sont-ils toujours présents ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?",
"url": "https://questionsmedicales.fr/mesh/D014412#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Infections à virus oncogènes",
"description": "Comment prévenir les infections à virus oncogènes ?\nLa vaccination est-elle efficace contre tous les virus oncogènes ?\nQuels comportements à risque doivent être évités ?\nLes dépistages réguliers sont-ils recommandés ?\nL'éducation à la santé joue-t-elle un rôle dans la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D014412#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Infections à virus oncogènes",
"description": "Quels traitements sont disponibles pour ces infections ?\nLes traitements sont-ils différents selon le virus ?\nLa vaccination peut-elle prévenir ces infections ?\nLes traitements sont-ils efficaces à tous les stades ?\nY a-t-il des effets secondaires aux traitements ?",
"url": "https://questionsmedicales.fr/mesh/D014412#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Infections à virus oncogènes",
"description": "Quelles complications peuvent survenir avec ces infections ?\nLes infections à virus oncogènes augmentent-elles le risque de cancer ?\nPeut-on avoir plusieurs infections à virus oncogènes ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D014412#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Infections à virus oncogènes",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque d'infection ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe mode de vie affecte-t-il le risque d'infection ?\nLes infections chroniques augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D014412#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une infection à virus oncogène ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins, biopsies et techniques d'imagerie."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les virus oncogènes ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests PCR, sérologiques et l'analyse histologique sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les marqueurs tumoraux sont-ils utiles dans le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains marqueurs tumoraux peuvent indiquer une infection virale oncogène."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer ces infections par des symptômes ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent orienter le diagnostic, mais des tests sont nécessaires."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'historique médical dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'historique médical aide à identifier les facteurs de risque et les expositions."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des infections à virus oncogènes ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure fatigue, douleurs, et signes de cancer localisé."
}
},
{
"@type": "Question",
"name": "Les infections à virus oncogènes causent-elles des symptômes spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les symptômes varient selon le type de cancer et l'organe touché."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver à mesure que la maladie progresse."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certaines infections peuvent être asymptomatiques pendant longtemps."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent ressembler à ceux d'autres infections ou maladies."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections à virus oncogènes ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut la vaccination, l'éducation et des pratiques sexuelles sûres."
}
},
{
"@type": "Question",
"name": "La vaccination est-elle efficace contre tous les virus oncogènes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la vaccination est spécifique à certains virus, comme le HPV et l'hépatite B."
}
},
{
"@type": "Question",
"name": "Quels comportements à risque doivent être évités ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les rapports sexuels non protégés et le partage de matériel d'injection."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils recommandés ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dépistages réguliers peuvent aider à détecter précocement les cancers associés."
}
},
{
"@type": "Question",
"name": "L'éducation à la santé joue-t-elle un rôle dans la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation à la santé est cruciale pour sensibiliser aux risques et aux préventions."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour ces infections ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chimiothérapie, la radiothérapie et les antiviraux."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils différents selon le virus ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le traitement varie selon le type de virus et le cancer associé."
}
},
{
"@type": "Question",
"name": "La vaccination peut-elle prévenir ces infections ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines vaccinations, comme celles contre le HPV, peuvent prévenir des infections oncogènes."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à tous les stades ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité des traitements dépend du stade de la maladie au moment du diagnostic."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent entraîner des effets secondaires variés, comme la fatigue."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces infections ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent le développement de cancers et des maladies chroniques."
}
},
{
"@type": "Question",
"name": "Les infections à virus oncogènes augmentent-elles le risque de cancer ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont souvent liées à un risque accru de divers types de cancer."
}
},
{
"@type": "Question",
"name": "Peut-on avoir plusieurs infections à virus oncogènes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est possible d'être infecté par plusieurs virus oncogènes simultanément."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être traitées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent gravement affecter la qualité de vie et nécessiter des soins continus."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent l'exposition à des virus, le tabagisme et l'immunodépression."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'infection ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque d'infection et de cancer augmente avec l'âge."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque d'infections oncogènes."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque d'infection ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire le risque d'infections et de cancers associés."
}
},
{
"@type": "Question",
"name": "Les infections chroniques augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections chroniques peuvent augmenter le risque de développer des cancers."
}
}
]
}
]
}
Experimental Animal Center, Zunyi Medical University, Zunyi, 563099, China; Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, China. Electronic address: 1341481255@qq.com.
Publications dans "Infections à virus oncogènes" :
Laboratory of Veterinary Microbiology and Animal Infectious Diseases, College of Animal Sciences and Veterinary Medicine, Guangxi University, Nanning, 530004, Guangxi, China. Electronic address: 654956883@qq.com.
Publications dans "Infections à virus oncogènes" :
Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, China; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, 225009, China. Electronic address: shoveldeen@shvri.ac.cn.
Publications dans "Infections à virus oncogènes" :
McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, 53705, USA. Electronic address: megan.spurgeon@wisc.edu.
Publications dans "Infections à virus oncogènes" :
Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, P. R. China.
Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, 311121, P. R. China.
Publications dans "Infections à virus oncogènes" :
Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, China Medical University, Ministry of Education, Shenyang, 110001, P. R. China.
Phase I Clinical Trails Center, The First Hospital of China Medical University, Shenyang, 110102, P. R. China.
Publications dans "Infections à virus oncogènes" :
Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, China Medical University, Ministry of Education, Shenyang, 110001, P. R. China.
Phase I Clinical Trails Center, The First Hospital of China Medical University, Shenyang, 110102, P. R. China.
Publications dans "Infections à virus oncogènes" :
BK virus-associated nephropathy (BKVAN), caused by infection with or reactivation of BK virus, remains a challenge in kidney transplantation. Screening is recommended for all kidney transplant recipie...
This review aimed to examine the benefits and harms of interventions for BK virus infection in kidney transplant recipients....
We searched the Cochrane Kidney and Transplant Register of Studies up to 5 September 2024 through contact with the Information Specialist using search terms relevant to this review. Studies in the Reg...
All randomised controlled trials (RCTs) and cohort studies investigating any intervention for the treatment or prevention of BKVAN for kidney transplant recipients....
Two authors independently assessed the study quality and extracted data. Summary estimates of effect were obtained using a random-effects model, and results were expressed as risk ratios (RR) and thei...
Twelve RCTs (2669 randomised participants) were included. Six studies were undertaken in single centres, and six were multicentre studies; two of these were international studies. The ages of those pa...
Intense monitoring early after transplantation for BK viruria and BK viraemia is effective in improving BK virus infection outcomes as it helps with early detection of the infection and allows for a t...
BK virus (BKV; human polyomavirus 1) infections are asymptomatic in most individuals, and the virus persists throughout life without harm. However, BKV is a threat to transplant patients and those wit...
Reactivation of JC and BK polyomaviruses during immunosuppression can lead to adverse clinical outcomes. In renal transplant recipients, BKV-associated nephropathy can result in graft loss, while in p...
Comprehensive sequence characterisation of each preparation using short- and long-read next-generation sequencing technologies was performed with additional corroborative independent digital PCR (dPCR...
The analysed genomes displayed subpopulations frequently characterised by complex gene re-arrangements, duplications and deletions....
Despite the recognition of such polymorphisms using high-resolution sequencing methodologies, the ability of these reference materials to act to enhance assay harmonisation did not appear significantl...
Several studies have reported the presence of JC virus (JCV) in human tumors, The association of JCV and CRC remains controversial. This study aimed to evaluate the rearranged NCCR region of the detec...
In this case-control study, tumor tissues (n = 60), adjacent normal tissues (n = 60), and urine samples (n = 60) of the CRC patients were collected. The nested PCR was employed to detect the VP1 and N...
The analysis reveals that JCV DNA was detected in 35/60 (58.3%) tumor tissues, while 36/60 (60.0%) of adjacent normal tissues (p = 0.85). JCV DNA was detected in 42/60 (70.0%) urine samples when compa...
A significant proportion of 35%> of the tumor tissue and urine samples of the CRC patients was found to be positive for JCV DNA (P = 0.25). The parallel analysis of tumor and urine samples for JCV DNA...
Human polyomavirus BK (BKPyV) causes associated nephropathy and contributes to urinary tract cancer development in renal transplant recipients. Large tumor antigen (LT) is an early protein essential i...
The BKPyV LT nucleotide was synthesized, and the protein was expressed by transfection into permissive cells. The BKPyV LT protein was immunoprecipitated and subjected to LC-MS/MS analysis to determin...
BKPyV LT acetylation sites were identified at Lys3 and Lys230 by mass spectrometry. HDAC3 and HDAC8 and their deacetylation activity are required for BKPyV LT expression. In addition, mutations of Lys...
HDAC3 is a newly identified protein that interacts with BKPyV LT, and LT acetylation plays a vital role in the BKPyV life cycle....
BK virus-associated hemorrhagic cystitis (BKV-HC) is an intractable complication leading to higher mortality and prolonged hospitalization among allogeneic hematopoietic stem cell transplantation (all...
We searched relevant studies from PubMed, EMBASE, and the Cochrane Library up to February 2023. The odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) of all risk factors were calc...
Overall, 11 studies involving 2556 allo-HCT recipients were included in this meta-analysis. All included studies were retrospective and published between 2013 and 2022. We found that male sex (OR = 1....
Our meta-analysis indicated that male sex, haploidentical donor, myeloablative conditioning, aGVHD, cGVHD, and CMV reactivation were potential risk factors for BKV-HC....
Immunosuppressant reduction (ISR) is a common treatment for kidney transplant recipients experiencing infections, but its impacts on kidney transplant outcomes remains unclear. This retrospective sing...
Polyomavirus (BKV) infection can lead to major complications and damage to the graft in kidney transplant recipients (KTRs). We investigated whether pretransplant BK serostatus and BK-specific cell-me...
A total of 93 donor-recipient pairs who underwent kidney transplantation (KT) and 44 healthy controls were examined. Assessment of donor and recipient BKV serostatus and BKV-CMI in recipients was perf...
Anti-BKV IgG antibody was detected in 74 (79.6%) of 93 KTRs and in 68 (73.1%) of 93 KT donors. A greater percentage of KTRs who received allograft from donors with high levels of anti-BKV IgG had post...
Our study highlights the importance of pretransplant BKV-IgG serostatus and BKV-specific CMI in predicting posttransplant BKV infection in KTRs. The combination of high donor BKV-IgG, low recipient BK...
Despite the superior tumor lytic efficacy of oncolytic viruses (OVs), their systemic delivery still faces the challenges of limited circulating periods, poor tumor tropism, and spontaneous antiviral i...
This study aims to evaluate the presence of EBV, HCMV, and BKV genomic sequences in the plasma samples (active infection/viremia) of kidney transplant recipients suspected of rejection and to investig...
In this cross-sectional single-center study, plasma samples were collected from 98 suspected kidney transplant rejection patients at Labafinejad Hospital, Tehran, Iran, between December 2022 and June ...
HCMV active viremia was detected in 18 (18.36%) recipients, EBV active viremia in 7 (7.14%), and BKV active viremia in 5 (5.10%). ROC results indicated viral load cutoff points of 778, 661, and 457 po...
Rapid and timely diagnosis of viral active infections in kidney transplant patients is crucial for effective disease management and implementation of appropriate treatment strategies. Identifying pote...